Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr 1;34(7):856-80.
doi: 10.15252/embj.201490784. Epub 2015 Feb 23.

Autophagy in malignant transformation and cancer progression

Lorenzo Galluzzi  1 , Federico Pietrocola  2 , José Manuel Bravo-San Pedro  2 , Ravi K Amaravadi  3 , Eric H Baehrecke  4 , Francesco Cecconi  5 , Patrice Codogno  6 , Jayanta Debnath  7 , David A Gewirtz  8 , Vassiliki Karantza  9 , Alec Kimmelman  10 , Sharad Kumar  11 , Beth Levine  12 , Maria Chiara Maiuri  2 , Seamus J Martin  13 , Josef Penninger  14 , Mauro Piacentini  15 , David C Rubinsztein  16 , Hans-Uwe Simon  17 , Anne Simonsen  18 , Andrew M Thorburn  19 , Guillermo Velasco  20 , Kevin M Ryan  21 , Guido Kroemer  22
Affiliations
Review

Autophagy in malignant transformation and cancer progression

Lorenzo Galluzzi et al. EMBO J. .

Abstract

Autophagy plays a key role in the maintenance of cellular homeostasis. In healthy cells, such a homeostatic activity constitutes a robust barrier against malignant transformation. Accordingly, many oncoproteins inhibit, and several oncosuppressor proteins promote, autophagy. Moreover, autophagy is required for optimal anticancer immunosurveillance. In neoplastic cells, however, autophagic responses constitute a means to cope with intracellular and environmental stress, thus favoring tumor progression. This implies that at least in some cases, oncogenesis proceeds along with a temporary inhibition of autophagy or a gain of molecular functions that antagonize its oncosuppressive activity. Here, we discuss the differential impact of autophagy on distinct phases of tumorigenesis and the implications of this concept for the use of autophagy modulators in cancer therapy.

Keywords: Beclin 1; KRAS; adaptive stress responses; inflammation; mitophagy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
General organization of autophagic responses Autophagy initiates with the progressive segregation of cytoplasmic material by double-membraned structures commonly known as phagophores or isolation membranes. Phagophores nucleate from the endoplasmic reticulum (ER), but several other membranous organelles have been shown to contribute to their elongation, including the Golgi apparatus, ER-Golgi intermediate compartment (ERGIC), plasma membrane, mitochondria and recycling endosomes. Completely sealed phagophores, which are known as autophagosomes, fuse with lysosomes to form autolysosomes. This promotes the activation of lysosomal hydrolases and hence causes the breakdown of the autophagosomal cargo. The products of these catabolic reactions reach the cytosol via transporters of the lysosomal membrane and are recycled by anabolic or bioenergetic circuitries.
Figure 2
Figure 2
Oncosuppressive functions of autophagy Autophagy has been proposed to suppress malignant transformation by several mechanisms, including: (1) the preservation of genetic/genomic stability; (2) the disposal of endogenous sources of potentially mutagenic reactive oxygen species (ROS); (3) the maintenance of normal bioenergetic functions; (4) the degradation of oncogenic proteins; (5) cell-endogenous antiviral and antibacterial effects; (6) the optimal activation of oncogene-induced senescence (OIS) and oncogene-induced cell death (OICD); (7) the maintenance of a normal stem cell compartment; (8) multipronged anti-inflammatory functions; and (9) a key role in the elicitation and execution of anticancer immunosurveillance. ABL1, ABL proto-oncogene 1; APC, antigen-presenting cell; BCL10, B-cell CLL/lymphoma 10; BCR, breakpoint cluster region; CTL, cytotoxic T lymphocyte; TP53mut, mutant tumor protein p53; PML, promyelocytic leukemia; RARA, retinoic acid receptor, alpha; RHOA, ras homolog family member.
Figure 3
Figure 3
Tumor-supporting functions of autophagy Once malignant transformation has occurred, autophagy is believed to promote tumor progression and resistance to therapy. Such tumor-supporting functions reflects the ability of autophagy to: (1) improve the resistance of cancer cells to endogenous conditions that normally provoke cell death, such as the detachment from the basal membrane, hypoxia and nutrient deprivation; (2) render transformed cells less sensitive to therapy-induced cell death; (3) sustain the survival of cancer cells that enter a state of dormancy or senescence in response to therapy; and (4) ensure the maintenance of the cancer stem cell compartment. EMT, epithelial-to-mesenchymal transition.
Figure 4
Figure 4
Autophagy in malignant transformation and tumor progression (A) Healthy cells appear to be protected from malignant transformation by proficient autophagic responses. Conversely, autophagy promotes tumor progression and therapy resistance in a variety of models. Thus, the transition of a healthy cell toward a metastatic and therapy-insensitive neoplasm may involve a temporary (but not a stable) loss in autophagy competence. The mechanisms underlying the restoration of proficient autophagic responses after malignant transformation remain to be elucidated. (B, C) In specific settings, oncogenesis and tumor progression may rely on a permanent loss (B) or gain (C) of autophagic proficiency.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abida WM, Gu W. p53-Dependent and p53-independent activation of autophagy by ARF. Cancer Res. 2008;68:352–357. - PMC - PubMed
    1. Ahn CH, Jeong EG, Lee JW, Kim MS, Kim SH, Kim SS, Yoo NJ, Lee SH. Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS. 2007;115:1344–1349. - PubMed
    1. Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, Kalachikov S, Gilliam TC, Levine B. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics. 1999;59:59–65. - PubMed
    1. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007;117:326–336. - PMC - PubMed
    1. Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 2014;51:219–227. - PubMed

Publication types

Substances